BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...Elpis said the investment is part of a new strategic partnership with a global pharmaceutical companyCASI, BioInvent...
...develop BI-1206 in liquid and solid cancers, with CASI responsible for commercialization in mainland China, Taiwan, Hong Kong and Macau. BioInvent...
...milestones plus tiered royalties. BC Staff Ultragenyx Pharmaceutical Inc. Scholar Rock Holding Corp. Galecto Inc. Citrine Medicine Co. Ltd. Bioprojet Pharma S.a.r.l. BioInvent International AB CASI...
BioCentury | Oct 24, 2017
Company News

Management tracks: Five Prime, CytoSen

...the Pierre Fabre Fund for Innovation at Laboratoires Pierre Fabre S.A. (Castres, France). Immuno-oncology company BioInvent International AB...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

...the Phase III EUCLID trial to prevent cardiovascular events in patients with peripheral arterial disease BioInvent International AB...
BioCentury | Dec 30, 2016
Company News

BioInvent, Pfizer deal

...BioInvent and Pfizer partnered to develop antibodies against tumor-associated myeloid cells. BioInvent will receive upfront and...
...pharma will purchase 21.9 million shares at SEK2.56. The price is a 28% premium to BioInvent's...
...respond to inquiries. BioInvent International AB (SSE:BINV), Lund, Sweden Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer Chris Lieu BioInvent International AB Pfizer...
BioCentury | Dec 30, 2016
Clinical News

BI-505: Ph II discontinued

...the trial last November following an adverse cardiopulmonary event (see BioCentury, Nov. 14, 2016 ). BioInvent International AB...
...bone marrow immune cell composition and phenotype, and pharmacokinetics Status: Phase II discontinued Milestone: NA Julian Zhu BI-505 BioInvent International AB Intercellular...
BioCentury | Dec 22, 2016
Company News

BioInvent, Pfizer in cancer antibody deal

...after announcing a partnership with Pfizer Inc. (NYSE:PFE) to develop antibodies against tumor-associated myeloid cells. BioInvent...
...pharma will purchase 21.9 million shares at SEK2.56. The price is a 28% premium to BioInvent's...
...be eligible for more than $500 million in milestones, plus royalties up to double digits. BioInvent...
BioCentury | Nov 10, 2016
Clinical News

BI-505: Ph II hold

...the trial and that the patient has recovered. BioInvent said it is determining next steps. BioInvent International AB...
...bone marrow immune cell composition and phenotype and pharmacokinetics Status: Phase II hold Milestone: NA Chris Lieu BI-505 BioInvent International AB Intercellular...
BioCentury | Nov 8, 2016
Clinical News

BioInvent MM candidate on clinical hold

...therapy in patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) with high-dose melphalan. BioInvent...
...ICAM-1 ; CD54) has Orphan Drug designation in the U.S. and EU for the indication. Chris Lieu BI-505 BioInvent International AB Intercellular...
BioCentury | May 9, 2016
Clinical News

TB-403: Phase I/IIa started

...Oncurious and BioInvent began an open-label, U.S. Phase I/IIa of IV TB-403 in >=27 patients ages...
...the Flanders Institute for Biotechnology (Ghent, Belgium), has worldwide, co-development rights to TB-403 for cancer. BioInvent...
...antibodies against PlGF in 2004 (see BioCentury, Jan. 3, 2005). Oncurious N.V. , Leuven, Belgium BioInvent International AB...
BioCentury | Apr 25, 2016
Clinical News

BI-505: Phase II started

...BI-505 as an add-on therapy in about 90 patients undergoing autologous stem cell transplantation (ASCT). BioInvent International AB...
Items per page:
1 - 10 of 220
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...Elpis said the investment is part of a new strategic partnership with a global pharmaceutical companyCASI, BioInvent...
...develop BI-1206 in liquid and solid cancers, with CASI responsible for commercialization in mainland China, Taiwan, Hong Kong and Macau. BioInvent...
...milestones plus tiered royalties. BC Staff Ultragenyx Pharmaceutical Inc. Scholar Rock Holding Corp. Galecto Inc. Citrine Medicine Co. Ltd. Bioprojet Pharma S.a.r.l. BioInvent International AB CASI...
BioCentury | Oct 24, 2017
Company News

Management tracks: Five Prime, CytoSen

...the Pierre Fabre Fund for Innovation at Laboratoires Pierre Fabre S.A. (Castres, France). Immuno-oncology company BioInvent International AB...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

...the Phase III EUCLID trial to prevent cardiovascular events in patients with peripheral arterial disease BioInvent International AB...
BioCentury | Dec 30, 2016
Company News

BioInvent, Pfizer deal

...BioInvent and Pfizer partnered to develop antibodies against tumor-associated myeloid cells. BioInvent will receive upfront and...
...pharma will purchase 21.9 million shares at SEK2.56. The price is a 28% premium to BioInvent's...
...respond to inquiries. BioInvent International AB (SSE:BINV), Lund, Sweden Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer Chris Lieu BioInvent International AB Pfizer...
BioCentury | Dec 30, 2016
Clinical News

BI-505: Ph II discontinued

...the trial last November following an adverse cardiopulmonary event (see BioCentury, Nov. 14, 2016 ). BioInvent International AB...
...bone marrow immune cell composition and phenotype, and pharmacokinetics Status: Phase II discontinued Milestone: NA Julian Zhu BI-505 BioInvent International AB Intercellular...
BioCentury | Dec 22, 2016
Company News

BioInvent, Pfizer in cancer antibody deal

...after announcing a partnership with Pfizer Inc. (NYSE:PFE) to develop antibodies against tumor-associated myeloid cells. BioInvent...
...pharma will purchase 21.9 million shares at SEK2.56. The price is a 28% premium to BioInvent's...
...be eligible for more than $500 million in milestones, plus royalties up to double digits. BioInvent...
BioCentury | Nov 10, 2016
Clinical News

BI-505: Ph II hold

...the trial and that the patient has recovered. BioInvent said it is determining next steps. BioInvent International AB...
...bone marrow immune cell composition and phenotype and pharmacokinetics Status: Phase II hold Milestone: NA Chris Lieu BI-505 BioInvent International AB Intercellular...
BioCentury | Nov 8, 2016
Clinical News

BioInvent MM candidate on clinical hold

...therapy in patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) with high-dose melphalan. BioInvent...
...ICAM-1 ; CD54) has Orphan Drug designation in the U.S. and EU for the indication. Chris Lieu BI-505 BioInvent International AB Intercellular...
BioCentury | May 9, 2016
Clinical News

TB-403: Phase I/IIa started

...Oncurious and BioInvent began an open-label, U.S. Phase I/IIa of IV TB-403 in >=27 patients ages...
...the Flanders Institute for Biotechnology (Ghent, Belgium), has worldwide, co-development rights to TB-403 for cancer. BioInvent...
...antibodies against PlGF in 2004 (see BioCentury, Jan. 3, 2005). Oncurious N.V. , Leuven, Belgium BioInvent International AB...
BioCentury | Apr 25, 2016
Clinical News

BI-505: Phase II started

...BI-505 as an add-on therapy in about 90 patients undergoing autologous stem cell transplantation (ASCT). BioInvent International AB...
Items per page:
1 - 10 of 220